Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
Biotech Reimagined: From Capital Constraints to Scientific Momentum at the 2026 Yale Innovation Summit